prikaz prve stranice dokumenta Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment
  Download
PDF 1.05 MB
Scientific paper - Original scientific paper
Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment
Journal of Alzheimer's Disease, 50 (2016), 3; 765-778. https://doi.org/10.3233/JAD-150705
Babić Leko, Mirjana; Borovečki, Fran; Dejanović, Nenad; Hof, Patrick R.; Šimić, Goran

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Babić Leko, M., Borovečki, F., Dejanović, N., Hof, P. R. & Šimić, G. (2016). Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment. Journal of Alzheimer's Disease, 50. (3), 765-778. doi: 10.3233/JAD-150705

Babić Leko, Mirjana, et al. "Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment." Journal of Alzheimer's Disease, vol. 50, no. 3, 2016, pp. 765-778. https://doi.org/10.3233/JAD-150705

Babić Leko, Mirjana, Fran Borovečki, Nenad Dejanović, Patrick R. Hof and Goran Šimić. "Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment." Journal of Alzheimer's Disease 50, no. 3 (2016): 765-778. https://doi.org/10.3233/JAD-150705

Babić Leko, M., et al. (2016) 'Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment', Journal of Alzheimer's Disease, 50(3), pp. 765-778. doi: 10.3233/JAD-150705

Babić Leko M, Borovečki F, Dejanović N, Hof PR, Šimić G. Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment. Journal of Alzheimer's Disease [Internet]. 2016 [cited 2024 April 28];50(3):765-778. doi: 10.3233/JAD-150705

M. Babić Leko, F. Borovečki, N. Dejanović, P. R. Hof and G. Šimić, "Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment", Journal of Alzheimer's Disease, vol. 50, no. 3, pp. 765-778, 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:599312. [Accessed: 28 April 2024]

Metadata
Title (english)Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment
AuthorMirjana Babić Leko
AuthorFran Borovečki
AuthorNenad Dejanović
AuthorPatrick R. Hof
AuthorGoran Šimić
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Visinin-like protein 1 (VILIP-1) recently emerged as a potential biomarker of Alzheimer's disease (AD). This neuronal calcium sensor protein previously used as a marker of acute ischemic stroke is elevated in the cerebrospinal fluid (CSF) of AD patients. The goal of this study was to assess CSF VILIP-1 potential in early AD diagnosis and in differentiating mild cognitive impairment (MCI) patients with and without risk of AD. Additionally, we tested VILIP-1 ability to differentiate AD from other primary causes of dementia, and predict the progression of AD-related cognitive decline. VILIP-1 levels were compared with five CSF AD biomarkers (t-tau, Aβ1-42, p-tau181, p-tau199, and p-tau231). VILIP-1 successfully differentiated two MCI patient groups characterized by absence or presence of pathological levels of these CSF biomarkers, except for t-tau. VILIP-1/Aβ(1-42) and VILIP-1/p-tau181 ratios also differentiated MCI patients with pathological CSF biomarker levels. However, there was no difference in VILIP-1 levels between AD and MCI patients. VILIP-1/Aβ(1-42) and VILIP-1/p-tau231 ratios reached high sensitivities (above 70%) and very high specificities (above 85%) in differentiating AD patients from HC. Additionally, VILIP-1 differentiated AD from patients with Lewy body disease with 77.1% sensitivity and 100% specificity. VILIP-1 potential as a prognostic biomarker of cognitive decline in AD was also proved since VILIP-1/t-tau, VILIP-1/p-tau181, and VILIP-1/p-tau231 ratios correlated with MMSE scores. These data indicate that VILIP-1 alone or in combination with other AD CSF biomarkers represent a valuable marker for the early diagnosis of AD, recognition of MCI patients at higher risk to develop dementia, and in differentiating AD from LBD.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleJournal of Alzheimer's Disease
Numberingvol. 50, no. 3, pp. 765-778
p-ISSN1387-2877
DOIhttps://doi.org/10.3233/JAD-150705
URN:NBNurn:nbn:hr:105:599312
Publication2016
Document URLhttps://doi.org/10.3233/JAD-150705
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 08:53:11